The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.
Lucchini, M., Bianco, A., Del Giacomo, P., De Fino, C., Nociti, V., Mirabella, M., Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report, <<MULTIPLE SCLEROSIS AND RELATED DISORDERS>>, 2020; 44 (44): N/A-N/A. [doi:10.1016/j.msard.2020.102323] [http://hdl.handle.net/10807/165255]
Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report
Lucchini, Matteo;Bianco, Assunta;Del Giacomo, Paola;De Fino, Chiara;Nociti, Viviana;Mirabella, Massimiliano
2020
Abstract
The emergency represented by the COVID-19 pandemic represents a new challenge for clinicians who deal with autoimmune diseases because of patients undergoing immunosuppressive therapy. Few cases of Multiple Sclerosis (MS) patients receiving ocrelizumab who contracted COVID-19 with a benign course have recently been published. We present the case of a MS patient with mild COVID-19 who developed SARS-CoV-2 specific IgA without IgG ten weeks after infection. Patients on B-cell depleting drugs have a reduced antibody immune response to viral neoantigens. A relative sparing of mucosal-associated lymphoid tissues (MALT) could be responsible for IgA response in our patient.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
